Alder's migraine drug attracted plenty of dealmakers. The company, not so much

In search of a partner that could help market its main drug outside the U.S., Alder BioPharmaceuticals contacted more than 20 parties. While a handful of them expressed interest, only one showed "any indication" of wanting to pursue an all-out acquisition of the company, according to a regulatory document filed Monday.